Osteoprotegerin to soluble receptor activator of nuclear factor κ-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3

European Journal of Haematology

Volumn 74, Issue 4, 2005, Pages 359-361

  Voskaridou, Ersi ^a   Terpos, Evangelos ^b,c,d  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b General Airforce Hospital   (Greece)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; COLECALCIFEROL; DEOXYPYRIDINOLINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TARTRATE RESISTANT ACID PHOSPHATASE ISOFORM 5B; UNCLASSIFIED DRUG;

BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMUR NECK; FOREARM; HUMAN; HYPOGONADISM; LETTER; LUMBAR SPINE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THALASSEMIA MAJOR;

BONE DENSITY; BONE REMODELING; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHOLECALCIFEROL; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; THALASSEMIA;

EID: 16244369752     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00395.x     Document Type: Letter

References (14)

1. WONKE B. Bone disease in β-thalassemia major. Br J Haematol 1998;103:897-901.
2. HOROWITZ MC, XI Y, WILSON K, KACENA MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18.
3. VOSKARIDOU E, KYRTSONIS MC, TERPOS E, SKORDILI M, THEODOROPOULOS I, BERGELE A, DIAMANTI E, KALOVIDOURIS A, LOUTRADI A, LOUKOPOULOS D. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001;112:36-41.
4. TERPOS E, SZYDLO R, APPERLEY JF, HATJIHARISSI E, POLITOU M, MELETIS J, VINIOU N, YATAGANAS X, GOLDMAN JM, RAHEMTULLA A. Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-1069.
5. LASCO A, MORABITO N, GAUDIO A, BUEMI M, WASNIEWSKA M, FRISINA N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-575.
6. KONG YY, YOSHIDA H, SAROSI I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
7. SIMONET WS, LACEY DL, DUNSTAN CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
8. YANO K, TSUDA E, WASHIDA N, KOBAYASHI F, GOTO M, HARADA A, IKEDA K, HIGASHIO K, YAMADA Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-527.
9. MORABITO N, GAUDIO A, LASCO A, ATTERITANO M, PIZZOLEO MA, CINCOTTA M, LA ROSA M, GUARINO R, MEO A, FRISINA N. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004;19:722-727.
10. ZHANG D, YANG YQ, LI XT, FU MK. The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha, 25-dihydroxyvitamin D3. Arch Oral Biol 2004;49:71-76.
11. KONDO T, KITAZAWA R, MAEDA S, KITAZAWA S. 1α,25-Dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res 2004;19:1411-1419.
12. VARGA F, SPITZER S, KLAUSHOFER K. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 2004;74:382-387.
13. UEDO Y, SHINKI T, NAGAI Y, MURAYAMA H, FUJII K, SUDA T. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003;90:267-277.
14. VOSKARIDOU E, TERPOS E. New insights into pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-139.